Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/73752
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Oliveira, Isabel Matos | por |
dc.contributor.author | Fernandes, Diogo Castro | por |
dc.contributor.author | Maia, F. Raquel | por |
dc.contributor.author | Canadas, Raphael Faustino | por |
dc.contributor.author | Reis, R. L. | por |
dc.contributor.author | Oliveira, J. M. | por |
dc.date.accessioned | 2021-07-29T10:52:45Z | - |
dc.date.available | 2021-07-29T10:52:45Z | - |
dc.date.issued | 2021-07 | - |
dc.date.submitted | 2021-07 | - |
dc.identifier.citation | Oliveira I. M., Fernandes D. C., Maia F. R., Canadas R. F., Reis R. L., Dr. Oliveira J. M. Bioengineered Nanoparticles Loaded-Hydrogels to Target TNF Alpha in Inflammatory Diseases, Pharmaceutics, Vol. 13, Issue 8, pp. 1-14, doi:10.3390/pharmaceutics13081111, 2021 | por |
dc.identifier.issn | 1999-4923 | por |
dc.identifier.uri | https://hdl.handle.net/1822/73752 | - |
dc.description.abstract | Rheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic impairment of patientsâ mobility. For this reason, it is vital to develop therapies that target early inflammatory symptoms and act before permanent articular damage. The present study offers two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed approach showed potential for use as personalized medicine to obtain better therapeutic outcomes and decreased adverse effects. | por |
dc.description.sponsorship | The authors thank the financial support provided under the Norte2020 project (NORTE-08-5369-FSE000044). D.C.F. acknowledges the Portuguese Foundation for Science and Technology (FCT) for her PhD scholarship (PD/BD/143081/2018) and F.R.M. for her contract under the Transitional Rule DL 57/2016 (CTTI-57/18-I3BS(5)). The FCT distinction attributed to J.M.O. under the Investigator FCT program (number IF/01285/2015) is also greatly acknowledged. | por |
dc.language.iso | eng | por |
dc.publisher | MDPI | por |
dc.relation | NORTE-08-5369-FSE000044 | por |
dc.relation | PD/BD/143081/2018 | por |
dc.relation | IF/01285/2015 | por |
dc.rights | openAccess | por |
dc.subject | Bioreactor | por |
dc.subject | Dendrimers | por |
dc.subject | Dynamic conditions | por |
dc.subject | Nanocomposite hydrogels | por |
dc.subject | Static conditions | por |
dc.subject | Therapeutic efficacy | por |
dc.title | Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/13/8/1111 | por |
dc.comments | http://3bs.uminho.pt/node/20551 | por |
oaire.citationIssue | 8 | por |
oaire.citationVolume | 13 | por |
dc.date.updated | 2021-07-23T14:07:30Z | - |
dc.identifier.doi | 10.3390/pharmaceutics13081111 | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Pharmaceutics | por |
Aparece nas coleções: | 3B’s - Artigos em revistas/Papers in scientific journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
20551-pharmaceutics-13-01111-2.pdf | 9,26 MB | Adobe PDF | Ver/Abrir |